Fc Engineering for Enhanced Antibody Efficacy and Half-Life
The Fc (fragment crystallizable) region of antibodies plays a crucial role in mediating immune effector functions and determining antibody pharmacokinetics. Fc engineering has become a strategic tool in antibody drug discovery to improve therapeutic efficacy and half-life, propelling growth in the Antibody Drug Discovery Market.
By modifying Fc glycosylation patterns or amino acid sequences, scientists can enhance antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or modulate interactions with Fc receptors on immune cells. These changes amplify the antibody’s ability to recruit the immune system to eliminate diseased cells.
Moreover, Fc modifications can extend serum half-life by improving binding to the neonatal Fc receptor (FcRn), reducing dosing frequency and improving patient compliance. Novel Fc variants also aim to reduce immunogenicity and adverse effects.
This precision engineering requires an in-depth understanding of Fc structure-function relationships and is supported by computational modeling and high-throughput screening. Fc-engineered antibodies are increasingly prevalent in oncology, autoimmune, and infectious disease therapies.